TrimRX | CagriSema Dosing Guide: Schedule, Titration & What to Expect Each Week

Introduction

CagriSema is a once-weekly subcutaneous injection that combines semaglutide and cagrilintide in a single pen. Dosing follows a titration schedule similar to other GLP-1 therapies, starting at a low combined dose and stepping up over 16-20 weeks to maintenance. The pace of titration controls side effects, and slower titration generally produces fewer GI symptoms.

The expected maintenance dose is 2.4 mg semaglutide plus 2.4 mg cagrilintide, the regimen used in REDEFINE 1 phase 3 trial. Starter doses begin at 0.25 mg of each component, matching the Wegovy® starter dose for semaglutide alone. The titration takes about 16-20 weeks to reach maintenance for most patients, with some staying at intermediate doses if side effects are problematic.

This article walks through what each titration step looks like, what patients typically feel during each phase, and what to discuss with a prescriber if titration doesn’t go smoothly. The drug isn’t yet FDA-approved, but the protocol is well-defined from the REDEFINE program and from cagrilintide phase 2 dose-finding studies. TrimRx providers will use this protocol once CagriSema is available, and the same logic applies to current compounded semaglutide dosing.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is the Standard CagriSema Titration Schedule?

The expected titration mirrors the REDEFINE phase 3 protocol. Starting dose is 0.25 mg semaglutide plus 0.25 mg cagrilintide for 4 weeks. Step 2 is 0.5 mg of each for 4 weeks. Step 3 is 1.0 mg of each for 4 weeks. Step 4 is 1.7 mg of each for 4 weeks. Maintenance is 2.4 mg of each, taken indefinitely once reached.

Quick Answer: Once weekly subcutaneous injection in abdomen, thigh, or upper arm

Some patients tolerate the titration faster than 4 weeks per step. Others need slower escalation or extended time at intermediate doses. The titration is flexible and individualized. The principle is to reach maintenance with manageable side effects rather than to hit maintenance on schedule.

Each step doubles or substantially increases receptor activation, which is why side effects often peak in the first 1-2 weeks after a step up and then settle. Patients should plan for some GI symptoms after each titration step and adjust meal sizes, food choices, and hydration accordingly.

What Should I Expect During the First 4 Weeks (0.25 Mg)?

The starter dose is intentionally subtherapeutic. The goal is GI system adaptation, not weight loss. Most patients feel mild nausea, occasional fullness after meals, and modest appetite reduction. Weight loss in the first 4 weeks is typically 1-3 pounds, mostly water and small caloric reductions.

Common side effects in week 1: mild nausea, increased burping or fullness after eating, occasional headache. Some patients have no symptoms at all. The drug is in your system for a full week per injection, so symptoms tend to peak 2-3 days after each weekly shot and ease toward the next dose.

Hydration matters from day one. GLP-1 therapy reduces thirst signals along with appetite signals, and dehydration worsens nausea and constipation. Drink 64-96 oz of water daily. Electrolyte replacement (sodium, potassium, magnesium) helps if you’re working out or in a hot climate.

What Changes During Weeks 5-8 (0.5 Mg STEP)?

The 0.5 mg step is where most patients first notice meaningful appetite reduction. Portion sizes drop without effort. Some foods that were previously appealing now seem unappetizing. Weight loss accelerates to roughly 0.5-1.5 pounds per week.

GI side effects often increase the week after stepping up. Nausea may be more pronounced. Some patients have one or two episodes of vomiting after large or high-fat meals. The body adapts within 7-14 days for most people. If symptoms remain severe at the end of week 2 of the new dose, dropping back to the previous step is reasonable.

Many patients describe this phase as the “quiet food noise” stage. The constant background thinking about food fades. Decisions about what to eat become easier. This is the mechanism patients describe most when they talk about how GLP-1 therapy feels qualitatively different from willpower-based dieting.

What Happens at the 1.0 Mg STEP (Weeks 9-12)?

The 1.0 mg dose is the standard maintenance dose for type 2 diabetes with semaglutide monotherapy. For CagriSema obesity treatment, it’s an intermediate step. Weight loss often accelerates as the cagrilintide component starts contributing meaningfully to satiety.

GI side effects typically taper at this step rather than escalate, because the body has now adapted to GLP-1 receptor activation. Some patients have a new wave of mild nausea the first week after stepping up; most resolve quickly. Constipation may emerge or worsen because slowed gastric emptying compounds with reduced fluid intake.

Weight loss at week 12 is commonly in the 6-10% range from baseline for patients who started at typical obesity BMI. This is in line with the REDEFINE 1 trajectory at the equivalent timepoint. Patients who lose less or more than this range are within normal variation; individual response differs substantially.

What About the 1.7 Mg STEP (Weeks 13-16)?

The 1.7 mg dose is roughly the “maintenance minus one step” position. Some patients stay here long-term if they’re tolerating well and achieving their weight loss goals. Others continue to the full 2.4 mg target. The decision is individualized based on response and side effects.

Side effects at this step are usually a continuation of the prior pattern rather than new issues. Persistent constipation, occasional reflux, and gradual reduction in food enjoyment are the most common chronic effects. Most patients accept these as the cost of meaningful weight loss.

Lean body mass loss becomes more of a concern at higher doses. Resistance training 2-3 times per week and protein intake of 1.0-1.6 g/kg/day help preserve muscle during weight loss. Patients who don’t train and don’t increase protein may lose 25-35% of weight loss as lean mass, which is more than ideal.

Key Takeaway: First 4-8 weeks: GI side effects most common (nausea, occasional vomiting)

What Does the Full 2.4 Mg Maintenance Dose Feel Like?

At the maintenance dose, most patients feel a stable rhythm of reduced appetite and predictable side effects. Food noise is low. Portions are small. Many patients describe a “natural” stopping point during meals that they didn’t experience pre-treatment. Energy levels are generally maintained or improved as weight loss progresses.

Weight loss continues but typically slows after week 30-40. The REDEFINE 1 mean trajectory shows steady weight loss to about week 50, with plateau development in the final months of the 68-week trial. End-of-trial weight loss was 22.7% mean, with substantial individual variation.

Once you’ve reached maintenance and stabilized, the question shifts to long-term continuation. CagriSema, like other GLP-1 therapy, requires ongoing dosing to maintain weight loss. Stopping leads to gradual weight regain over months to years.

How Do I Handle a Missed CagriSema Dose?

The missed-dose rule depends on how late you are. If you’re less than 5 days late, take the missed dose as soon as you remember and continue your normal weekly schedule. If you’re 5 days or more late, skip the missed dose and take the next scheduled dose at the regular time. Don’t double-dose to catch up.

For patients who travel or change time zones frequently, sticking to a consistent injection day of the week (e.g., every Sunday morning) is easier than tying it to a specific clock time. The drug has a 7-day half-life, so a few hours flexibility in timing doesn’t affect efficacy.

If you miss two or more consecutive doses, the receptor occupancy drops enough that resuming at the previous maintenance dose can cause more side effects than expected. In that case, dropping back one titration step for 2-4 weeks before re-escalating is reasonable. TrimRx providers handle missed-dose questions through the patient portal.

When and How Should the Dose Be Reduced?

Dose reduction is appropriate in three scenarios. First, persistent intolerance: if side effects are severe at any step and don’t resolve within 2-3 weeks, dropping back to the previous dose stabilizes the patient. Second, target achievement: if the patient has reached their weight loss goal at an intermediate dose, staying there for maintenance is reasonable instead of pushing to maximum dose. Third, lean body mass concerns: if rapid lean mass loss is occurring, slowing the titration or holding at a lower dose protects muscle.

Severe side effects warranting prompt dose reduction or pause include intractable vomiting, severe abdominal pain (possible pancreatitis), gallbladder symptoms (right upper quadrant pain), and signs of dehydration. These warrant immediate prescriber contact regardless of titration position.

For patients on insulin or sulfonylureas, hypoglycemia is the trigger for dose adjustment. The semaglutide component improves glycemic control independently, so background insulin and sulfonylurea doses often need reduction during CagriSema titration to avoid lows.

What’s the Optimal Injection Technique?

Subcutaneous injection in the abdomen, thigh, or upper arm. The abdomen is most common because of easy access and consistent absorption. Avoid the 2-inch zone around the navel and any areas with scars, stretch marks, or lipohypertrophy. Rotate sites weekly to prevent fatty tissue changes from repeated injection in one spot.

Inject at room temperature. Allow the pen to warm from refrigerator temperature for 15-30 minutes before injection to reduce stinging. Clean the skin with alcohol and let it dry fully before injection. Pinch the skin gently, insert the needle at 90 degrees, push the dose button slowly, and hold for 6 seconds before withdrawing. Dispose of the needle in a sharps container.

Injection day flexibility is reasonable. Many patients pick a consistent day (Sunday is common) and time (morning is common) to build a habit. Some patients prefer evening dosing if morning nausea is worse than evening nausea. Either timing works pharmacologically.

Bottom line: Maintenance: 2.4 mg semaglutide + 2.4 mg cagrilintide weekly indefinitely

FAQ

Can I Take CagriSema with Food?

Yes. The injection isn’t related to meal timing because semaglutide and cagrilintide both have 7-day half-lives. Eat normally on injection day. Many patients reduce meal sizes naturally during the 24-48 hours after the shot when satiety effects are strongest.

How Quickly Will I Lose Weight on CagriSema?

Weight loss usually starts in week 1-2 and accelerates as the dose escalates. Average loss is 1-2 pounds per week during early titration and 0.5-1.5 pounds per week during maintenance. Total weight loss at 68 weeks in REDEFINE 1 was 22.7% mean.

What If I Can’t Tolerate the 0.25 Mg Starting Dose?

Some patients are very sensitive to GLP-1 effects. Options include extending the starter dose for 6-8 weeks instead of 4, splitting the dose timing differently, or pausing for 1-2 weeks before resuming. If 0.25 mg is truly intolerable, the drug may not be the right fit for that patient.

Can I Skip Dose Escalations and Jump to Maintenance?

No. Skipping steps causes severe nausea, vomiting, and dehydration. The titration exists for a reason. Patients who try to accelerate often end up dropping the drug entirely because of intolerable side effects.

Should I Take CagriSema in the Morning or Evening?

Either works. Pick the time that fits your schedule and stick with it. The drug doesn’t have a peak effect related to clock time because of its 7-day half-life. Consistency aids adherence more than time-of-day choice.

How Do I Know If I’m at the Right Dose?

The right dose is the one that produces meaningful weight loss with tolerable side effects. If you’re losing weight steadily and feeling well, the dose is right. If you’ve plateaued and side effects are gone, going up a step is reasonable. If side effects are unmanageable, going down a step is appropriate.

Will I Need to Be on CagriSema Forever?

Probably yes, to maintain weight loss. The GLP-1 class is generally used as long-term therapy. Stopping leads to gradual weight regain over 1-2 years. Some patients cycle on and off, but this typically results in less stable weight outcomes than continuous therapy.

Can I Switch From Wegovy to CagriSema?

Once approved, yes. The transition would likely involve continuing the current Wegovy dose and adding cagrilintide on the same schedule, or switching to the corresponding CagriSema combined dose. Prescriber guidance is essential for the transition.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

CagriSema Dosing Guide: Schedule, Titration & What to Expect Each Week

Table of Contents